Product news from the 08/29/06 News Brief

Share this article:
The FDA yesterday approved several abbreviated new drug applications for generic versions of Bayer’s Cipro intravenous, a drug to treat certain bacterial infections.  Ciprofloxacin Injection, is now indicated for the treatment of infections, including urinary tract infections, lower respiratory tract infections (including pneumonias in hospitalized patients, nosocomial pneumonia), bone and joint infections, complicated intraabdominal infections, skin and skin structure infections, and therapy of patients with fever and neutropenia.   The FDA has approved the use of UCB’s Keppra (levetiracetam) as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. Keppra is widely prescribed as an add-on therapy in the treatment of partial onset seizures in adults and children four years of age and older with epilepsy.
Share this article:

Email Newsletters

More in Business Briefs

FDA approves Glaxo's GLP-1

Type-2 diabetes injection Tanzeum, also known as albiglutide, scored the approval Tuesday.

Insurers get personal to nip costs

Healthcare insurers seek to curb diabetes costs with interventions that may include house calls.

Novartis dials down RNA research

The drugmaker says the therapeutic approach has a narrow treatment potential.